Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial
- PMID: 36166027
- PMCID: PMC9516287
- DOI: 10.1001/jama.2022.15613
Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial
Abstract
Importance: The benefit of high-flow nasal cannula oxygen (high-flow oxygen) in terms of intubation and mortality in patients with respiratory failure due to COVID-19 is controversial.
Objective: To determine whether the use of high-flow oxygen, compared with standard oxygen, could reduce the rate of mortality at day 28 in patients with respiratory failure due to COVID-19 admitted in intensive care units (ICUs).
Design, setting, and participants: The SOHO-COVID randomized clinical trial was conducted in 34 ICUs in France and included 711 patients with respiratory failure due to COVID-19 and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen equal to or below 200 mm Hg. It was an ancillary trial of the ongoing original SOHO randomized clinical trial, which was designed to include patients with acute hypoxemic respiratory failure from all causes. Patients were enrolled from January to December 2021; final follow-up occurred on March 5, 2022.
Interventions: Patients were randomly assigned to receive high-flow oxygen (n = 357) or standard oxygen delivered through a nonrebreathing mask initially set at a 10-L/min minimum (n = 354).
Main outcomes and measures: The primary outcome was mortality at day 28. There were 13 secondary outcomes, including the proportion of patients requiring intubation, number of ventilator-free days at day 28, mortality at day 90, mortality and length of stay in the ICU, and adverse events.
Results: Among the 782 randomized patients, 711 patients with respiratory failure due to COVID-19 were included in the analysis (mean [SD] age, 61 [12] years; 214 women [30%]). The mortality rate at day 28 was 10% (36/357) with high-flow oxygen and 11% (40/354) with standard oxygen (absolute difference, -1.2% [95% CI, -5.8% to 3.4%]; P = .60). Of 13 prespecified secondary outcomes, 12 showed no significant difference including in length of stay and mortality in the ICU and in mortality up until day 90. The intubation rate was significantly lower with high-flow oxygen than with standard oxygen (45% [160/357] vs 53% [186/354]; absolute difference, -7.7% [95% CI, -14.9% to -0.4%]; P = .04). The number of ventilator-free days at day 28 was not significantly different between groups (median, 28 [IQR, 11-28] vs 23 [IQR, 10-28] days; absolute difference, 0.5 days [95% CI, -7.7 to 9.1]; P = .07). The most common adverse events were ventilator-associated pneumonia, occurring in 58% (93/160) in the high-flow oxygen group and 53% (99/186) in the standard oxygen group.
Conclusions and relevance: Among patients with respiratory failure due to COVID-19, high-flow nasal cannula oxygen, compared with standard oxygen therapy, did not significantly reduce 28-day mortality.
Trial registration: ClinicalTrials.gov Identifier: NCT04468126.
Conflict of interest statement
Figures
Comment in
-
Respiratory Support in the Time of COVID-19.JAMA. 2022 Sep 27;328(12):1203-1205. doi: 10.1001/jama.2022.15229. JAMA. 2022. PMID: 36166049 No abstract available.
Similar articles
-
Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial.JAMA. 2021 May 4;325(17):1731-1743. doi: 10.1001/jama.2021.4682. JAMA. 2021. PMID: 33764378 Free PMC article. Clinical Trial.
-
Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial.JAMA. 2018 Nov 27;320(20):2099-2107. doi: 10.1001/jama.2018.14282. JAMA. 2018. PMID: 30357270 Free PMC article. Clinical Trial.
-
Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial.JAMA. 2022 Sep 20;328(11):1063-1072. doi: 10.1001/jama.2022.15599. JAMA. 2022. PMID: 36125473 Free PMC article. Clinical Trial.
-
High-flow nasal cannulae for respiratory support in adult intensive care patients.Cochrane Database Syst Rev. 2017 May 30;5(5):CD010172. doi: 10.1002/14651858.CD010172.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2021 Mar 4;3:CD010172. doi: 10.1002/14651858.CD010172.pub3. PMID: 28555461 Free PMC article. Updated. Review.
-
The Effect of High-Flow Nasal Cannula Oxygen Therapy on Mortality and Intubation Rate in Acute Respiratory Failure: A Systematic Review and Meta-Analysis.Crit Care Med. 2017 Apr;45(4):e449-e456. doi: 10.1097/CCM.0000000000002091. Crit Care Med. 2017. PMID: 27611978 Review.
Cited by
-
High-flow nasal oxygen therapy compared with conventional oxygen therapy in hospitalised patients with respiratory illness: a systematic review and meta-analysis.BMJ Open Respir Res. 2024 Jul 15;11(1):e002342. doi: 10.1136/bmjresp-2024-002342. BMJ Open Respir Res. 2024. PMID: 39009460 Free PMC article.
-
Dyspnea is severe and associated with a higher intubation rate in de novo acute hypoxemic respiratory failure.Crit Care. 2024 May 23;28(1):174. doi: 10.1186/s13054-024-04903-5. Crit Care. 2024. PMID: 38783367 Free PMC article. Clinical Trial.
-
Acute Respiratory Failure From Early Pandemic COVID-19: Noninvasive Respiratory Support vs Mechanical Ventilation.CHEST Crit Care. 2024 Mar;2(1):100030. doi: 10.1016/j.chstcc.2023.100030. Epub 2023 Nov 24. CHEST Crit Care. 2024. PMID: 38645483 Free PMC article.
-
Challenges for a broad international implementation of the current severe community-acquired pneumonia guidelines.Intensive Care Med. 2024 Apr;50(4):526-538. doi: 10.1007/s00134-024-07381-z. Epub 2024 Mar 28. Intensive Care Med. 2024. PMID: 38546855 Review.
-
Noninvasive respiratory support in the emergency department: Controversies and state-of-the-art recommendations.J Am Coll Emerg Physicians Open. 2024 Mar 7;5(2):e13118. doi: 10.1002/emp2.13118. eCollection 2024 Apr. J Am Coll Emerg Physicians Open. 2024. PMID: 38464331 Free PMC article. Review.
References
-
- World Health Organization . WHO coronavirus (COVID-19) dashboard. Accessed January 12, 2022. https://covid19.who.int
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical